A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Public ClinicalTrials.gov record NCT04206553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses. Bullous pemphigoid is an autoimmune subepidermal blistering disease, predominately affecting the elderly (typical onset after age 60). The study is looking at several other research questions, including: * Side effects that may be experienced by people taking dupilumab * How dupilumab works in the body and affects the body * How dupilumab affects quality of life * How much dupilumab is present in the blood * To see if dupilumab works to wean the patient off oral corticosteroids
Study identification
- NCT ID
- NCT04206553
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2020 (Actual)
- Primary completion
- Jul 12, 2024 (Actual)
- Completion
- Jan 5, 2025 (Actual)
- Last update posted
- Jun 18, 2026
2020 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron study Site | Birmingham | Alabama | 35233 | — |
| Regeneron Study Site | Scottsdale | Arizona | 85259 | — |
| Regeneron Study Site | Redwood City | California | 94063 | — |
| Regeneron Study Site | Farmington | Connecticut | 06030 | — |
| Regeneron Study Site | Miami | Florida | 33125 | — |
| Regeneron study Site | Orlando | Florida | 32827 | — |
| Regeneron Study Site | Iowa City | Iowa | 52242 | — |
| Regeneron Study Site | Boston | Massachusetts | 02116 | — |
| Regeneron study Site | Ann Arbor | Michigan | 48109-5314 | — |
| Regeneron Study Site | Chapel Hill | North Carolina | 27516 | — |
| Regeneron Study Site | Portland | Oregon | 97239 | — |
| Regeneron Study Site | Philadelphia | Pennsylvania | 19104 | — |
| Regeneron study Site | Providence | Rhode Island | 02908 | — |
| Regeneron Study Site | Murray | Utah | 84107 | — |
| Regeneron study Site | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04206553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04206553 live on ClinicalTrials.gov.